JPRN-UMIN000037777
Completed
未知
Efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer other than adenocarcinoma or squamous cell carcinoma: multicenter retrospective observational study - Efficacy of ICI in patients with NSCLC other than adenocarcinoma or squamous cell carcinoma in a multi-center retrospective study
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- on-small cell lung cancer other than adenocarcinoma or squamous cell carcinoma
- Sponsor
- Hamamatsu University School of Medicine
- Enrollment
- 60
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients with no or insufficient clinical information
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
The usefulness of immune checkpoint inhibitors among lung cancer patients with driver gene mutantsung cancerJPRN-UMIN000040789Yokohama City University
Recruiting
Not Applicable
Predictive biomarker study of immune checkpoint inhibitors in metastatic head and neck squamous cell carcinomaNeoplasmsKCT0007598ational Cancer Center50
Completed
Not Applicable
Efficacy and safety of immune checkpoint inhibitors alone or in combination with chemotherapy in pulmonary sarcomatoid carcinomaPulmonary sarcomatoid carcinomaJPRN-UMIN000046002Kobe University124
Recruiting
Not Applicable
A real-world study of efficacy and safety of Immune check point inhibitors in patients with non-small cell lung cancer harboring driver oncogene excepting EGFRJPRN-UMIN000049022orth East Japan Study Group870
Not yet recruiting
Not Applicable
Administration of immune checkpoint inhibitors through an elastomeric pump. A patient preference study and cost analysis.Solid tumors for which nivolumab or pembrolizumab monotherapy has an EMA approved indication. This includes (but is not limited to) melanoma, renal-cell cancer, NSCLC and head and neck cancer.NL-OMON25676Erasmus MC390